Real Chemistry Nurtures Biotech Innovation with New Solution
The company’s new integrated solution helps emerging biotech companies ‘nail the narrative’ when it comes to securing investment capital, talent and clinical trial participants.
NEW YORK (Oct. 16, 2023) – Real Chemistry, the leading provider of AI-driven insights and marketing and communications for the healthcare industry, announced today that it is offering a new integrated solution for emerging biotech companies. Despite continued negative predictions that the Inflation Reduction Act will hinder innovation and that capital markets will remain constrained, there is still funding for biotech leaders who can clearly convey how they’ll bring game-changing therapies to the patients who may benefit the most. Real Chemistry’s new solution will help start-ups navigate capital-constrained operating environments and help them focus on getting to the next value inflection point with minimal cash burn.
“We know there is a true need in the market,” says Mary Claire Duch, Deputy Group President and Lead, Biotech Communications. “Since our inception, Real Chemistry has been a strategic adviser to leading biotech companies, both small and large, to help them improve their visibility, convey their narrative, acquire funding and establish new partnerships. We want to do our part to help continue to stimulate healthcare innovation by nurturing start-ups who are really doing groundbreaking work.”
The new integrated solution combines Real Chemistry’s robust real-world data and AI-enabled analytics with the strategic counsel of market access and marketing professionals who have deep expertise in the life sciences industry.
“Some of our early-stage biotech clients were initially hesitant to engage in discussions, believing that real-world data and advanced analytics would be out of their budget,” says Dan Fisher, Practice Leader, Data and AI Solutions. “We were pleased to demonstrate our partnership, supplying empirical data that were both accessible and affordable to clients early in the drug discovery process.”
Modern biotechnology helps provide breakthrough products and technologies to combat a wide range of ailments — from rare and orphan diseases to pandemics and lifestyle disorders. It is the science generating new critical, life-changing therapies like targeted medicines for cancer patients, gene therapies for rare diseases and biologics for autoimmune disorders, among others. Real Chemistry has been an integral part of many of these journeys through a combination of data, AI and decades of industry leading expertise.
“We know from working with leading pharma and biotech companies that the current environment can be challenging, especially when thinking about the experience of emerging biotech start-ups,” says Duch. “These small companies are incubators helping engineer a new blueprint for healthier communities. At Real Chemistry, we want to ensure we help nurture these innovators with tools that can transform their business, attract the right investors and help them to recruit both leading research talent and critically important clinical trial participants.”
Real Chemistry’s new integrated service will help biotech companies build a strong foundational corporate narrative that:
-
“Right-sizes” the market. Real Chemistry will work with emerging biotech companies to help validate funding opportunities by quantifying disease burden and appropriately sizing markets, activities that can be quite complicated when focusing on rare or hard-to-diagnose conditions.
-
Offers proof of impact. Using patient journey mapping, care pathways and information from key opinion leaders and organizations, Real Chemistry will help provide a clear, real-world data story of how patients and caregivers may benefit from the science.
-
Demonstrates multi-stakeholder value and engagement. As part of the package, emerging biotech companies will work with communications professionals with deep biotech expertise to crystallize their organization’s story, and build strategies tailored for specific audiences such as boards of directors, investors, key opinion leaders and advocacy groups.
-
Enables and differentiates the client’s brand. The package includes executive communications coaching that will help emerging biotech leaders nail innovative pitches that demonstrate human impact and clearly articulate strong value propositions for investors and other stakeholders.
In addition to the integrated service offering, biotech companies can access other premium services, such as additional stakeholder research, clinical trial planning and recruitment including diversity, equity and inclusion objectives, robust media and activation planning.
“We are committed to creating a healthier tomorrow, and that starts with helping our brightest innovators translate unparalleled insights into action,” says Duch.
Is your scientific value story ready for prime time? type: asset-hyperlink id: 3cSiAthDv0jiVnyfbkadWy or email nailthenarrative@realchemistry.com.
About Real Chemistry
Real Chemistry’s mission is to transform what healthcare is to what it should be by leveraging the industry’s most advanced AI-powered insights, diverse expertise and customer-centric ideas. We help the healthcare industry better understand, reach and engage patients and professionals – while creating healthcare experiences that span diagnosis to adherence – to ensure therapies meet and exceed their potential to impact lives.
